AI주식인사이트AI Stock Insight
C

파라택시스코리아

288330KOSDAQ기초 의약물질 제조업

49.0 / 100

Reference Date: 2026-04-13

Financial Score19.5 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Plunged 50.8% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Parataxis Korea operates two main business segments: digital assets and biotechnology. In the digital asset division, the company holds Bitcoin as a strategic financial asset and aims to generate revenue through mining operations. The biotechnology division focuses on developing innovative drugs for unmet medical needs, with key candidates like BBT-207 and BBT-877 currently in clinical trials for lung cancer and idiopathic pulmonary fibrosis, respectively.

Number of Employees

16people

Average Salary

74.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 27.774.0Point
PBR
1.60Industry Average 2.044.0Point

In line with industry avg

ROE
-82.55Industry Average -2.963.5Point

27.9x industry avg (excellent)

Debt Ratio
21.50Industry Average 29.085.0Point

Lower than industry avg (good)

Trend 2022~20243.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼97.3% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲30.1% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -100.6% (improving, 2yr)

Detailed News Sentiment

3 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 416Won52-week high 8,96052-week low 416
1-month return0.0Point

1m -50.83% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

16 totalPositive 0Neutral 16Negative 0
  • Neutral[기재정정]정기주주총회결과 (속회)2026-04-10
  • Neutral[기재정정]주요사항보고서(회사합병결정)2026-04-09
  • Neutral[기재정정]주주명부폐쇄기간또는기준일설정2026-04-08
  • Neutral[기재정정]정기주주총회결과2026-04-08
  • Neutral기타시장안내 (상장적격성 실질심사 대상결정 기한 안내)2026-04-08